

## Erratum to: Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

Ralf Gold · Giancarlo Comi · Jacqueline Palace · Arno Siever · Rebecca Gottschalk ·  
Mahendra Bijarnia · Philipp von Rosenstiel · Davorka Tomic · Ludwig Kappos ·  
For the FIRST Study Investigators

Published online: 4 March 2014  
© Springer-Verlag Berlin Heidelberg 2014

**Erratum to: J Neurol (2014) 261:267–276**  
**DOI 10.1007/s00415-013-7115-8**

The original version of this article unfortunately contained a mistake. The affiliation of the second author (Giancarlo Comi) is incorrect. The correct affiliation should be:

Department of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

---

The online version of the original article can be found under  
doi:[10.1007/s00415-013-7115-8](https://doi.org/10.1007/s00415-013-7115-8).

---

R. Gold (✉)  
Department of Neurology, St Josef Hospital, Ruhr-University,  
Gudrunstr. 56, 44791 Bochum, Germany  
e-mail: Ralf.gold@ruhr-uni-bochum.de

G. Comi  
Department of Neuroscience, San Raffaele Scientific Institute,  
Vita-Salute San Raffaele University, Milan, Italy

J. Palace  
Department of Clinical Neurology, Oxford University Hospitals  
Trust, Oxford, UK

A. Siever  
Gemeinschaftspraxis, Oldenburg, Germany

R. Gottschalk  
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

M. Bijarnia  
Novartis Healthcare Pvt Ltd, Hyderabad, India

P. von Rosenstiel · D. Tomic  
Novartis Pharma AG, Basel, Switzerland

L. Kappos  
Department of Neurology, University Hospital, Basel,  
Switzerland